寶蘭德(688058.SH):高管史曉麗及股東王凱擬合計減持不超30.8799萬股
格隆匯8月2日丨寶蘭德(688058.SH)公佈,截止公吿披露日,高級管理人員史曉麗持公司90萬股, 佔公司總股本的比例為 2.25%。股東王凱持有公司35.3799萬股,佔公司總股本的0.88%,上述股份全部為公司首次公開發行前取得的股份,並已於2020年11月2日解除限售並上市流通。
因個人資金需求,史曉麗計劃以集中競價、大宗交易的方式減持所持有的公司股份,合計減持不超過22.5萬股,即不超過公司總股本的0.5625%;
王凱計劃以集中競價、大宗交易的方式減持所持有的公司股份,合計減持不超過8.3799萬股,即不超過公司總股本的0.2095%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.